SCOPUS 정보 검색 플랫폼

European Journal of Pediatrics

Volumn 162, Issue 7-8, 2003, Pages 522-523

Enzyme replacement therapy in an adolescent with Fabry disease

(4) Illsinger, Sabine a Luecke, Thomas a Langen, Hendrik a Das, Anibh M a

a HANNOVER MEDICAL SCHOOL (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; CARBAMAZEPINE;

ADOLESCENCE; ADOLESCENT; ARTICLE; AUTONOMIC NERVOUS SYSTEM FUNCTION; CASE REPORT; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FABRY DISEASE; HUMAN; MALE; NEUROPATHIC PAIN; PAIN ASSESSMENT; PEDIGREE ANALYSIS; PRIORITY JOURNAL; SIDE EFFECT; TREATMENT OUTCOME;

ADOLESCENT; ALPHA-GALACTOSIDASE; FABRY DISEASE; HUMANS; ISOENZYMES; MALE; PEDIGREE;

EID: 0042347929 PISSN: 03406199 EISSN: None Source Type: Journal
DOI: 10.1007/s00431-003-1222-y Document Type: Article

Times cited : (6)

References (6)

1
- 0014216741
- Enzymatic defect in Fabry disease
- Brady RO, Gal AE, Bradley RM, Martensson E, Warshew AL, Laster L (1967) Enzymatic defect in Fabry disease. N Eng J Med 276: 1163-1167
- (1967) N Eng J Med , vol.276 , pp. 1163-1167
- Brady, R.O.¹ Gal, A.E.² Bradley, R.M.³ Martensson, E.⁴ Warshew, A.L.⁵ Laster, L.⁶

2
- 0036984003
- Pain assessment: The advantages of using pain scales in lysosomal storage diseases
- Cleeland CS (2002) Pain assessment: the advantages of using pain scales in lysosomal storage diseases. Acta Paediatr Suppl 91: 43-47
- (2002) Acta Paediatr Suppl , vol.91 , pp. 43-47
- Cleeland, C.S.¹

3
- 0000889058
- α-galactosidase A deficiency: Fabry disease
- Scriver CR, Beaudet AL, Sly WS, Childs B, Kinzler KE, Vogelstein B (eds). McGraw Hill, New York
- Desnick JR, Ioannou YA, Eng CM (2001) α-galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Childs B, Kinzler KE, Vogelstein B (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw Hill, New York, pp 3733-3774
- (2001) The Metabolic and Molecular Bases of Inherited Disease, 8th Edn. , pp. 3733-3774
- Desnick, J.R.¹ Ioannou, Y.A.² Eng, C.M.³

4
- 0035097499
- A phase 1/2 clinical trial of enzyme replacement in Fabry disease: Pharmacokinetic, substrate clearance, and safety studies
- Eng CM, Banikazemi M, Gordon RE, Goldman M, Phelps R, Kim L, Gass A, Winston J, Dikman S, Fallon JT, Brodie S, Stacy CB, Mehta D, Parsons R, Norton K, O'Callaghan M, Desnick RJ (2001a) A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 68: 711-722
- (2001) Am J Hum Genet , vol.68 , pp. 711-722
- Eng, C.M.¹ Banikazemi, M.² Gordon, R.E.³ Goldman, M.⁴ Phelps, R.⁵ Kim, L.⁶ Gass, A.⁷ Winston, J.⁸ Dikman, S.⁹ Fallon, J.T.¹⁰ Brodie, S.¹¹ Stacy, C.B.¹² Mehta, D.¹³ Parsons, R.¹⁴ Norton, K.¹⁵ O'Callaghan, M.¹⁶ Desnick, R.J.¹⁷

5
- 0035811624
- A multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of recombinat human α-galactosidase A replacement therapy in Fabry disease
- Eng CM, Guffon N, Wilcox WR (2001b) A multicenter, randomized, double-blind, placebo-controlled study of the safety and efficacy of recombinat human α-galactosidase A replacement therapy in Fabry disease. N Eng J Med 345: 9-16
- (2001) N Eng J Med , vol.345 , pp. 9-16
- Eng, C.M.¹ Guffon, N.² Wilcox, W.R.³

6
- 0035816007
- Enzyme replacement therapy in Fabry disease
- Schiffmann R, Kopp JB, Austin III HA, Sabnis S, Moore DF, Weibel T, Balow J, Brady RO (2001) Enzyme replacement therapy in Fabry disease. JAMA 285: 2743-2749
- (2001) JAMA , vol.285 , pp. 2743-2749
- Schiffmann, R.¹ Kopp, J.B.² Austin H.A. III³ Sabnis, S.⁴ Moore, D.F.⁵ Weibel, T.⁶ Balow, J.⁷ Brady, R.O.⁸

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.